Ozempic and related GLP-1 drugs have taken Europe and North America by storm and have quickly become the darling of the ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Altimmune (ALT) has received a new Buy rating, initiated by UBS analyst, Eliana Merle. Eliana Merle has given her Buy rating due to a ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.

SINGAPORE’S authorities are reviewing advertisements that telemedicine providers have put up for certain weight-loss drugs, ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...

Q3 2024 Earnings Call Transcript November 6, 2024Amphastar Pharmaceuticals, Inc. misses on earnings expectations.